SGEN Seattle Genetics Inc.

68.44
-0.74  -1%
Previous Close 69.18
Open 68.69
Price To Book 8.65
Market Cap 11015737341
Shares 160,954,666
Volume 287,593
Short Ratio
Av. Daily Volume 902,500

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated.
SGN-LIV1A (I-SPY 2)
Neoadjuvant for newly diagnosed Stage 2 or 3 HER2 negative breast cancer
Phase 1/2 trial initiated early 2018.
SGN-LIV1A + KEYTRUDA
First-line triple negative breast cancer (TNBC)
Phase 2 completion of enrolment announced March 29, 2019.
Tisotumab Vedotin (innovaTV 204 )
Cervical Cancer
Phase 2 pivotal data March 28, 2019 noted 44% ORR. BLA to be filed later in 2019.
Enfortumab vedotin - EV201
Urothelial cancer
Phase 3 trial initiated 2Q 2017.
ADCETRIS and Opdivo
Relapsed Hodgkin Lymphoma
Phase 3 trial initiated mid-2017. Data from Phase 1/2 at ASH 2017 showed a 83% ORR and 62% CR.
ADCETRIS and Opdivo CM-812
Relapsed Hodgkin Lymphoma
Approval announced August 19, 2011.
ADCETRIS
Hodgkin lymphoma and Anaplastic large cell lymphoma
Phase 1/2 clinical hold placed on December 27, 2016 was lifted March 6, 2017. Enrollment halted June 19, 2017 due to safety.
Vadastuximab Talirine (SGN-CD33A)
Myelodysplastic syndrome (MDS)
Phase 1b updated data at SABCS December 7, 2017.
(Tucatinib ONT-380) and T-DM1
HER2+ Metastatic Breast Cancer (MBC)
Phase 2 data due 2019.
(Tucatinib ONT-380) + Herceptin and Xeloda - HER2CLIMB trial
HER2+ Metastatic Breast Cancer (MBC)
Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.
Vadastuximab Talirine (CASCADE)
Acute myeloid leukemia (AML) - cancer
sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018.
ADCETRIS in combination with chemotherapy ECHELON-1
Frontline Hodgkin lymphoma
Phase 2 trial initiated 3Q 2016.
SGN-CD19A
Frontline DLBCL cancer
FDA Approval announced November 16, 2018.
ADCETRIS in combination with chemotherapy - ECHELON-2
Frontline CD30-positive mature T-cell lymphomas - cancer
Approved August 17, 2015 under priority review.
ADCETRIS - AETHERA
Post-transplant Hodgkin lymphoma (HL) cancer
Approval announced November 9, 2017.
ADCETRIS
Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma
Phase 1b trial has been initiated - noted February 6, 2018.
Enfortumab vedotin and pembrolizumab
2nd-line Urothelial cancer
Phase 1b/2 trial has been initiated.
Ladiratuzumab Vedotin
Triple negative breast cancer (TNBC)
Phase 3 trial initiation announced July 9, 2018.
Enfortumab vedotin - EV-301
Urothelial cancer
Phase 2 dosing has commenced - noted July 12, 2018.
Tisotumab Vedotin (innovaTV 207)
Solid tumors
Phase 1/2 updated data presented at ESMO October 20. 2018.
Tisotumab Vedotin (innovaTV 201)
Recurrent Cervical Cancer
Phase 1 data February 11, 2019 noted ORR 42%.
Enfortumab vedotin EV-101
Urothelial cancer

Latest News

  1. Were Hedge Funds Right About Buying Seattle Genetics, Inc. (SGEN)?
  2. Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know
  3. Is Seattle Genetics's (NASDAQ:SGEN) 111% Share Price Increase Well Justified?
  4. Seattle Genetics' Adcetris Progresses Well Amid Competition
  5. 5 Oncology Companies That Are Set to Run
  6. See what the IHS Markit Score report has to say about Seattle Genetics Inc.
  7. Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher
  8. Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019
  9. Seattle Genetics Closes Enrollment in Cervical Cancer Study
  10. Seattle Genetics, Astellas Report Positive Cancer Study Data
  11. Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
  12. This Biotech Stock Toppled Despite Success In Bladder Cancer Study
  13. Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin
  14. Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
  15. Seattle Genetics Highlights Antibody-Drug Conjugate Innovation and Immuno-Oncology Program at the American Association for Cancer Research (AACR) Annual Meeting
  16. Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?
  17. ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates
  18. Pullback Strategies: 10 Stocks That Could Fall the Fastest